Incyte Corporation develops therapeutics for hematology/oncology, inflammation, and autoimmunity. Products include JAKAFI, MONJUVI, PEMAZYRE, ICLUSIG, ZYNYZ, and OPZELURA. Clinical-stage products include retifanlimab, axatilimab, INCA033989, and others. The company has collaborations with Novartis, Lilly, Agenus, Merus, MacroGenics, and Syndax. Products are sold to pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name in 2003. Incyte Corporation is headquartered in Wilmington, Delaware.
| Indicator | Value |
|---|---|
| PER | 503.6 |
| EV/EBITDA | 44.5 |
| Price/Free Cash Flow' | 69.8 |
| ROIC | 9.6% |
| Net Debt/EBITDA | 100.0 |